

COVID-19 Vaccines: primary series

Pfizer- BioNTech

new

10 microgram dose EUA for
5-11 yrs

30 microgram dose EUA for
12+ yrs

FDA Approved (full
licensure) for 16+ yrs

Consists of two doses given
21 days apart

Moderna

EUA for 18+ yrs

Consists of two doses
given 28 days apart

Johnson & Johnson

by Janssen

EUA for 18+ yrs

Consists of one dose

Pfizer-BioNTech pediatric vaccine

- [FDA emergency use authorized](#) and [CDC recommended](#) to prevent COVID19 in **children 5-11 years old**
- 2 dose series, 10µg (0.2ml) per dose, 21 days apart
 - Pfizer pediatric vial and dose is different than for adolescents/adults!
- Ongoing randomized, placebo-controlled trial: 4,700 children
- Safety: 1,444 recipients monitored for at least 2 months after 2nd dose
 - Most common side effects: injection site pain/redness/swelling, fatigue, headache, muscle, joint pain, chills, fever, swollen lymph nodes, nausea and decreased appetite
 - Pfizer, CDC and FDA will continue monitoring for myocarditis, pericarditis and other events of interest
- Effectiveness: Immune response in children 5-11y/o comparable to 16-25y/o
 - 90.7% effective in preventing COVID-19 in children 5-11y/o

Booster Vaccines for adults: 18yrs +

- **All LTCF residents and staff are eligible for booster vaccine by age/risk criteria. Timing of booster dose depends on primary series: which vaccine and when.**
- Eligible individuals may choose which vaccine to receive as a booster dose: mix/match is ok
- Consider risks and benefits of each product
 - > safety profile of booster vaccine is similar as for primary vaccine series
 - Discuss with healthcare provider for more information
- Use of any COVID-19 vaccine will boost immunity!

Booster dose eligibility: Pfizer and Moderna

Booster shots of the Pfizer or Moderna vaccine are now **recommended** if you:

- Got a Pfizer or Moderna vaccination at least six months ago, and
- Are 65 years or older, or
- Age 18+ who **are long-term care residents**, or
- Age 18+ who have underlying medical condition, or
- Age 18+ who are at increased risk of COVID-19 due to social inequity
- Age 18+ who work or live in high-risk settings. **This includes long-term care staff.**

Booster dose eligibility: Johnson & Johnson

Booster dose of Janssen (Johnson & Johnson) vaccine is recommended if you:

- Received a Janssen (Johnson & Johnson) primary dose at least two months ago and
- Age 18 years and older

Note: This includes long-term care residents and staff

Immunocompromised individuals and booster dose recommendations

Pfizer and Moderna:

- Moderately and severely immunocompromised people aged ≥ 18 years who completed an mRNA COVID-19 vaccine primary series and received an additional mRNA vaccine dose **may** receive a single COVID-19 booster dose (Pfizer-BioNTech, Moderna, or Janssen) at least 6 months after completing their third mRNA vaccine dose. In such situations, people who are moderately and severely immunocompromised may receive a total of four COVID-19 vaccine doses.

Johnson&Johnson:

- Moderately and severely immunocompromised people aged ≥ 18 years who received a single dose Janssen COVID-19 vaccine primary series **should** receive a single COVID-19 booster vaccine (Pfizer-BioNTech, Moderna or Janssen) at least 2 months (8 weeks) after receiving their initial Janssen primary dose. A person who received one primary dose of Janssen COVID-19 vaccine should not receive more than two COVID-19 vaccine doses.

www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-additional-dose

COVID-19 Vaccines: booster doses

Pfizer- BioNTech

FDA-Authorized and
CDC-recommended for
those ≥ 18 years
In high-risk groups

6 months after primary
series

Moderna

FDA-Authorized and
CDC-recommended for
those ≥ 18 years
In high-risk groups

6 months after primary
series

***booster is half-dose (50
micrograms or 0.25 ml)**

Johnson & Johnson


FDA-Authorized and
CDC-recommended for
those ≥ 18 years

2 months after primary
series

www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html

www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/COVID-19-Vaccine-Boosters.aspx






Job Aid – COVID-19 Vaccine Product Guide



COVID-19 Vaccine Product Guide

Check vaccine products before use to ensure administration to appropriate ages.

Refer to CDC product info for more details.

	5-11 years old		12+ years old		18+ years old	
	Pfizer	Pfizer	Pfizer (Comirnaty)	Janssen (J&J)	Moderna	
	Pending Approval  subject to change	Currently Available 	Pending Approval  subject to change			
Packaging						
Cap color	Orange cap	Purple	Gray cap	Blue cap	Red cap	
Doses per vial	10 doses	6 doses	6 doses	5 doses	14 (or 10) doses	
Package size	100 doses	1170 (or 450) doses	TBD	50 doses	140 (or 100) doses	
NDC # in VTrckS	95267-1055-04	59267-1000-02	TBD	59676-0580-15	80777-0273-98	
Administration						
Diluent	1.3 mL per vial	1.8 mL per vial	Do not mix	Do not mix	Do not mix	
Injection Volume–Primary	0.2 mL	0.3 mL	0.3 mL	0.5 mL	0.5 mL	
Injection Volume–Booster	N/A	same	TBD	same	0.25 mL*	
Storage Limits** (Store products on different shelves, labeled by age, to avoid mix-ups.)						
ULT (-90 to -60°C)	Up to 6 months [†]	Up to 9 months	Up to 6 months [†]	N/A	N/A	
Thermal Shipper	N/A	Up to 30 days	N/A	N/A	N/A	
Freezer	N/A	Up to 14 days (-25 to -15°C)	N/A	N/A	Until expiration (-50 to -15°C)	
Refrigerator (2° to 8°C)	Up to 10 weeks [†]	Up to 31 days	Up to 10 weeks [†]	Until expiration	Up to 30 days	

* When drawing up half-doses for Moderna boosters, note that Moderna vials cannot be punctured more than 20 times.

** Do not dispose of expired vaccine until checking with manufacturers for extended expiration dates.

† Regardless of storage condition, do not use vaccine after 6 months from manufacture date printed on vial/cartons.

California COVID-19 Vaccination Program IMM-1399 (10/22/21)

Guide includes:

- Packaging
- Administration
- Storage Limits
- Age
- Availability

[COVID-19 Vaccine Product Guide](#)

CDPH Toolkit for LTCF Vaccination Resources

Long-Term Care Facility (LTCF)

COVID-19 Vaccine Toolkit

The **LTCF COVID-19 Vaccine Toolkit** has been developed as a resource to ensure that Long-Term Care (LTC) residents and staff have continued access to primary series or booster doses of COVID-19 vaccine. The following are vaccine access options and resources.

https://eziz.org/assets/docs/COVID19/LTCF_Toolkit_10.01.21.pdf